Klarexyl

Clarithromycin, the active ingredient in Klarexyl, is a macrolide antibiotic presented as an oral dosage form for systemic use. It treats bacterial infections such as community‑acquired pneumonia, acute sinusitis, bronchitis exacerbations, skin infections and is used in Helicobacter pylori eradication regimens.

GNH USA supplies Klarexyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is indicated for several bacterial infections affecting the respiratory and skin systems.

Community‑acquired pneumonia: reduces bacterial load and improves clinical outcomes in adult patients. Acute bacterial sinusitis: alleviates sinus inflammation caused by susceptible organisms. Acute exacerbations of chronic bronchitis: shortens duration of symptoms and prevents complications. Skin and soft‑tissue infections: eradicates susceptible Gram‑positive and some Gram‑negative pathogens. Helicobacter pylori eradication: part of combination therapy to achieve bacterial clearance.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that may be mild to moderate. - Taste disturbance: a metallic or altered taste perception. - Abdominal pain: cramping or discomfort in the stomach area. - Headache: mild to moderate headache episodes.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes. - Cardiac arrhythmias: QT interval prolongation leading to irregular heartbeats. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Hematologic abnormalities: neutropenia or thrombocytopenia.

Before prescribing clarithromycin, consider patient‑specific factors and monitor for potential risks.

Assess liver function: avoid use in patients with severe hepatic impairment. Monitor cardiac status: caution in patients with known QT prolongation or electrolyte disturbances. Evaluate drug interactions: review concomitant medications that affect CYP3A4. Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Clarithromycin interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): risk of myopathy and rhabdomyolysis. - Certain antiarrhythmics (e.g., amiodarone, quinidine): may cause serious cardiac conduction disturbances.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, requiring closer coagulation monitoring. - Oral hypoglycemics (e.g., sulfonylureas): potential for enhanced hypoglycemia. - Anticonvulsants (e.g., carbamazepine): may reduce clarithromycin levels, decreasing efficacy.